bioMerieux (BMXMF) Stock Price, News & Analysis

Company Overview

bioMérieux (OTCMKTS:BMXMF) is a France-based company specializing in in vitro diagnostics. It develops, manufactures and markets diagnostic systems used to detect infectious diseases, support antimicrobial treatment decisions and improve patient care in clinical settings.

The company’s product portfolio includes molecular biology tests, microbiology systems, immunoassays and syndromic testing solutions. Its clinical diagnostic products are used by hospitals, laboratories and other healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetic industries through solutions for detecting microorganisms and monitoring contamination.

Established in 1963, bioMérieux traces its roots to the Mérieux family’s longstanding involvement in medical research and diagnostics in France. The company is headquartered near Lyon and serves customers through operations and distribution networks across international markets.

Key Stats

• Today's Range: $83.27 to $83.27
• 50-Day Range: $78.99 to $88.50
• 52-Week Range: $77.00 to $138.15
• Volume: 302 shs
• Average Volume: 357 shs
• Market Capitalization: $9.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

bioMerieux Stock Analysis - MarketRank™

bioMerieux scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

bioMerieux has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

bioMerieux has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 7.62%

Earnings Growth

Earnings for bioMerieux are expected to grow by 7.62% in the coming year, from $5.12 to $5.51 per share.

Price to Book Value per Share Ratio

bioMerieux has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.11% of the float of bioMerieux has been sold short.

Short Interest Ratio / Days to Cover

bioMerieux has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in bioMerieux has recently decreased by 0.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bioMerieux does not currently pay a dividend.

Dividend Growth

bioMerieux does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for bioMerieux this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bioMerieux insiders have not sold or bought any company stock.

Percentage Held by Institutions

bioMerieux has minimal institutional ownership at this time.

Company Calendar

• Today: 9/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BMXMF
• CIK: N/A
• Web: www.biomerieux.com
• Phone: 33-04-78-87-20-00
• Fax: 33-04-78-87-20-90
• Employees: 14,600
• Year Founded: 1963

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.39
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: $4.60 billion
• Price / Sales: 2.14
• Cash Flow: $9.15 per share
• Price / Cash Flow: 9.10
• Book Value: $39.25 per share
• Price / Book: 2.12

Miscellaneous

• Outstanding Shares: 118,360,000
• Free Float: N/A
• Market Cap: $9.86 billion
• Optionable: Not Optionable
• Beta: 0.77